Fda Accepts For Review Astrazeneca's Supplemental Biologics License Application For Self-Administration Of Flumist Quadrivalent
October 25, 2023
October 25, 2023
WILMINGTON, Delaware, Oct. 25 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Potential to be the first and only self-administered flu vaccine
* * *
AstraZeneca's Supplemental Biologics License Application (sBLA) for the approval of a self- or caregiver-administered option for FLUMIST(R) QUADRIVALENT (Influenza Vaccine Live, Intranasal), a needle-free nasal spray, has been accepted for review by th . . .
* * *
Potential to be the first and only self-administered flu vaccine
* * *
AstraZeneca's Supplemental Biologics License Application (sBLA) for the approval of a self- or caregiver-administered option for FLUMIST(R) QUADRIVALENT (Influenza Vaccine Live, Intranasal), a needle-free nasal spray, has been accepted for review by th . . .